Efficacy of novel bispecific antibody targeting TNF-α/CXCL10 in the treatment of experimental arthritis

K/BxN Serum-Transfer Arthritis as a Model for Human Inflammatory Arthritis

(2016) Anne D. Christensen et al.   Frontiers in Immunology

Anti-TNF therapy: past, present and future

(2014) C. Monaco et al.   INTERNATIONAL IMMUNOLOGY

Therapeutic effect of anti-C-X-C motif chemokine 10 (CXCL10) antibody on C protein-induced myositis mouse

(2014) Jinhyun Kim et al.   ARTHRITIS RESEARCH & THERAPY

A Phase II Randomized Study of Subcutaneous Ixekizumab, an Anti-Interleukin-17 Monoclonal Antibody, in Rheumatoid Arthritis Patients Who Were Naive to Biologic Agents or Had an Inadequate Response to Tumor Necrosis Factor Inhibitors

(2014) Mark C. Genovese et al.   Arthritis & Rheumatology

Expression of ICAM1 and VCAM1 Serum Levels in Rheumatoid Arthritis Clinical Activity. Association with Genetic Polymorphisms

(2013) Rosa Elena Navarro-Hernández et al.   DISEASE MARKERS

Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: Results from a randomized controlled trial

(2011) Maria W. Greenwald et al.   ARTHRITIS AND RHEUMATISM

The Pathogenesis of Rheumatoid Arthritis

(2011) Iain B. McInnes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Potential role and mechanism of IFN-gamma inducible protein-10 on receptor activator of nuclear factor kappa-B ligand (RANKL) expression in rheumatoid arthritis

(2011) Eun Lee et al.   ARTHRITIS RESEARCH & THERAPY

A Comparison of Patient Characteristics and Outcomes in Selected European and U.S. Rheumatoid Arthritis Registries

(2010) Jeffrey R. Curtis et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Reciprocal cross-talk between RANKL and interferon-γ–inducible protein 10 is responsible for bone-erosive experimental arthritis

(2008) Han Bok Kwak et al.   ARTHRITIS AND RHEUMATISM

CXCL10 and autoimmune diseases

(2008) Eun Young Lee et al.   AUTOIMMUNITY REVIEWS